|Articles|October 24, 2018

Obesity Algorithm Challenge: 8 Questions

Test your knowledge of the newly updated obesity algorithm from the Obesity Medicine Association with this 8-question challenge.

The Obesity Medicine Association (OMA) recently released the 2018 updates to The Obesity Algorithm® for pediatric and adult patients. How much do you know about obesity trends, categories, and treatments? Find out with our 8-question quiz below.

Question 1.

Please click here for answer and next question.

Answer: B. False. Between 2015 and 2016, the prevalence of obesity was higher among US adults (40%) vs youth (18.5%).

Question 2.

Please click here for answer and next question.

Answer: D. 35-39.9. A BMI between 18.5-24.9 kg/m²is classified as normal, 25.0-29.9 kg/m² is classified as overweight, 30.0-34.9 kg/m² is classified as class I obesity, 35-39.9 kg/m² is classified as class II obesity, and ≥40 kg/m² is classified as class III obesity.

Question 3.

Please click here for answer and next question.

Answer: D. 32%. In women, a body fat percentage of ≥32% is classified as overweight or obese.

Question 4.

Please click here for answer and next question.

Answer: B. False. DXA measures fat mass and lean soft tissue mass OR soft tissue mass and bone mineral mass, but not fat mass and soft tissue mass.

Question 5.

Please click here for answer and next question.

Answer: E. B and D. The prevalence of obesity was highest among non-Hispanic black and Hispanic adults vs non-Hispanic white and non-Hispanic Asian adults.

Question 6.

Please click here for answer and next question.

Answer: C. Orlistat. While orlistat (Alli, Xenical) is an FDA-approved anti-obesity drug, it was approved in 1999. Phentermine HCL/topiramate extended release (Qsymia) and lorcaserin (Belviq) were first approved in 2012 and liraglutide (Saxenda) was first approved in 2014.

Question 7.

Please click here for answer and next question.

Answer: A. <5000. <5000 steps taken per day is considered sedentary and this is the national average for US adults.

Question 8.

Please click here for answer.

Answer: A. True. The OMA recommends that patients walk 10 minutes for every hour they have been sitting.

References:

For more information, please visit www.obesityalgorithm.org.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

Obesity Algorithm Challenge: 8 Questions

References:

Newsletter

Related Content

Obesity Still Plagues the US, But Rates Are Declining in Some States: The Trust for America's Health Report

John Anderson, MD on How to Integrate CGM in Primary Care: "Just Do It"

Multidisciplinary Lung Cancer Screening Program Achieves Screening Rates Above 70%

The Menopause Society 2025 Annual Meeting: A Primary Care Preview

Real-Time CGM Reduces Risk of Large Newborns in Gestational Diabetes: Daily Dose

Latest CME

Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (Cope Credit)

Interventional Glaucoma: The Convergence of Surgical Innovation and Therapeutic Hope

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Expert Illustrations and Commentaries™: The Role of the Paracellular Pathway in the Management of Hyperphosphatemia in CKD

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision-Making and Future Therapies

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Identifying and Treating CIDP in the Modern Era

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Breast Cancer Symposia in San Antonio

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment

Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Community Practice Connections™: 21st Annual Meeting of the International Society of Gastrointestinal Oncology

Medical Crossfire®: Optimal Approaches to Evaluating and Addressing Pain in the Patient With Sickle Cell Disease

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Addressing Health Care Inequities™: Taking a More Mindful Approach to the Care of Every Patient Presenting With ATTR-CM

Clinical Case Vignette Series™: 3rd Annual International Congress on Pediatric Oncology

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Medical Crossfire®: Improving Survival in HR-Positive HER2-Negative Metastatic Breast Cancer – Advances in Selective Estrogen Receptor Targeting Therapies

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

Real Psychiatry 2026

23rd Annual Winter Lung Cancer Conference®

43rd Annual Miami Breast Cancer Conference®

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting

17th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention

Homing in on the Role of PSMA in Prostate Cancer – Harnessing the Power of Precision Medicine Through Imaging and Therapy to Individualize Treatment Plans

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

2nd Annual Hawaii Cancer Conference

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

Community Practice Connections™: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes

Raising Our Game in the Management of Hyperlipidemia: New Targets, New Tactics

Medical Crossfire®: New Horizons in Hemolytic Anemias – How I Diagnose & Treat Based on Individual Patient and Disease Characteristics

Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Expert Perspectives on Technological Advances in Cataract Surgery

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances